SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is experiencing high-volatility price action and massive call option volume as investors position for potential regulatory approvals and a major data center power partnership. Community sentiment remains deeply divided between long-term bulls betting on the company's AI-linked energy infrastructure and vocal critics focused on the lack of current revenue, pending litigation, and speculative leadership.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community anticipates potential news from the upcoming AACR conference, with investors closely watching for Phase 3 REGAL trial updates and new data on the SLS009 pipeline. Discussion is dominated by strong conviction among long-term holders regarding potential breakthrough results and a possible buyout, while debates persist over trial timelines, short interest, and the stock's recent volatility surrounding options expiration.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending following news that Greenland approved the transfer of a majority stake in the Tanbreez rare earth project, a significant catalyst that investors view as de-risking the asset and clearing a path for potential Western supply chain integration. The community is actively discussing the stock's long-term strategic value, with many bulls pointing to high short interest and institutional buying as indicators of an impending short squeeze.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor interest driven by a combination of strong technical support, ongoing short-squeeze potential, and anticipation surrounding upcoming data releases in May. Community sentiment remains focused on the company's platform potential in prostate and lung cancer, with long-term investors actively discussing institutional accumulation and the possibility of a future buyout.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is experiencing high volatility as investors weigh its potential for AI-driven design innovation against competitive threats from tools like Anthropic's Claude. While the community remains divided between those viewing the current sell-off as a generational buying opportunity and others worried about structural disruption to the SaaS design model, the stock is heavily focused on whether the company can maintain its role as a central creative hub.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as investors re-examine its 2011 origin story as the original crypto parody, with the community actively debating whether its long-standing cultural relevance and history of satire translate into long-term value. Discussion is currently dominated by claims of accumulation by high-profile wallets and the project's emergence as an authentic, irony-driven alternative in the current memecoin market.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp (BULL) is gaining significant momentum as investors digest a double catalyst involving the SEC's approval to eliminate the Pattern Day Trader rule and the company's decision to terminate a major dilutive financing agreement. Community discussions are heavily focused on high-volume accumulation, institutional confidence in the stock's valuation, and speculative bets on a potential short squeeze as traders anticipate a long-term recovery toward double-digit price targets.

Maulcoin

Maulcoin is capturing attention as a meme-driven project where the community is intensely focused on collective holding and building despite market volatility. Participants are actively engaging in 'maul challenges' and trending campaigns, while discussions frequently touch on distinguishing their project from similar meme tokens and managing the ups and downs of a decentralized community.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Mining Inc

Cipher Mining is trending as investors reprice the stock from a bitcoin miner to an AI-adjacent infrastructure and data center play, driven by a hyperscaler lease agreement and heavy institutional call activity. Despite recent volatility and broader sector pressure, the community is actively debating whether current levels represent an institutional shakeout or a technical entry point for a multi-day momentum run.

Daddy Darth Sidious

The community is rallying behind SIDIOUS as a high-volatility speculative asset, with traders actively debating its potential to mirror the momentum of previous meme-themed tokens. Enthusiasts are focusing on social media-driven hype and coordinated community efforts to sustain volume throughout the weekend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year High - Time to Buy?

Enliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month High - Should You Buy...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 26.3% in March

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totaling 6,053,456...

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.2% - What's Next?

Enliven Therapeutics (NASDAQ:ELVN) Trading Down 4.2% - What's Next...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to...

Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High - Should You Buy?

Enliven Therapeutics (NASDAQ:ELVN) Hits New 52-Week High - Here's What Happened...

Q1 EPS Estimate for Enliven Therapeutics Reduced by Analyst

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Enliven Therapeutics in a note issued to investors on Thursday...

Enliven Therapeutics (NASDAQ:ELVN) Given New $56.00 Price Target at HC Wainwright

HC Wainwright upped their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday...

Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High on Analyst Upgrade

Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High Following Analyst Upgrade...

<ul class="summary-bullets"><li>Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701, the analyst said.&nbsp;</li><li>Clear sees ELVN-001 as a lower-risk, high-upside asset.</li><li>The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation.</li></ul>Shares of Enliven Therapeutics Inc (ELVN) rallied 15% on Wednesday after Wall Street highlighted that Merck's (MRK) $6.7 billion acquisition of Terns Pharmaceuticals' (TERN) TERN-701 underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies, similar to the kind Enliven is developing.Clear Street noted the opportunity for CML therapies despite generics. The acquisition signals growing interest in CML beyond Novartis (NVS), it added. Chronic myeloid leukemia (CML) is a slow-growing blood cancer where the bone marrow produces too many myeloid cells.In this context, Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701 and multiple strategic paths to value, the firm argued.Clear sees ELVN-001 as a lower-risk, high-upside asset. The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation, pending U.S. Food and Drug Administration’s alignment on dose selection and trial design.<h2 class="st-heading-2">Merck-Terns Deal</h2>Merck said earlier on Wednesday that it has entered into a definitive agreement to acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion in a bid to add TERN-701 to its portfolio. TERN-701 is an experimental therapy currently in development for certain patients with CML. The transaction is expected to close in the second quarter of 2026, the company said, but analysts including RBC Capital and William Blair noted that it expects another bidder to emerge for Terns.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ELVN stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ELVN">ELVN stock</a> has gained 68% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/salesforce-reportedly-holding-back-on-raises-for-higher-level-employees/cZ3YDSyRISD">Salesforce Reportedly Holding Back On Raises For Higher-Level Employees</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Enliven Therapeutics, Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio

According to Clear Street, the Terns-Merck deal underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies.

Equity

According to Clear Street, the Terns-Merck deal underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies.


Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up After Analyst Upgrade

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

ELVN
Enliven Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ELVN News

ELVNEnliven Therapeutics Inc